Changeflow GovPing Healthcare & Life Sciences Syqe Medical Ltd. THC Inhaler, 0.75mg Max
Routine Notice Added Draft

Syqe Medical Ltd. THC Inhaler, 0.75mg Max

Favicon for changeflow.com USPTO Patent Applications - Pharma (A61K)
Published
Detected
Email

Summary

Syqe Medical Ltd. filed patent application US20260108542A1 on December 19, 2025 (application no. 19426146), published April 23, 2026, covering a THC inhaler system with a scheduled regimen that caps delivery at 0.75 mg THC or less over a minimum 2-hour period. The system includes a memory storing the regimen, a decision module that determines whether delivery should occur, and a controller in the inhaler device executing delivery based on those decisions. The named inventors include Perry Davidson, Seth Kindler, Shlomo Almog, Binyamin Schwartz, Aaron Schorr, and Daniella Atzmony.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.

What changed

Syqe Medical Ltd. filed a patent application covering a low-dose THC delivery system that stores a scheduled regimen defining a maximum of 0.75 mg THC delivered over 2 or more hours, with a decision module controlling whether doses are released and a controller executing delivery. The application is classified under CPC codes including A61K 31/658 (cannabis derivatives), A61M 15/009 (inhalers), and G16H 20/13 (digital therapeutics for drug delivery).

Patent applicants or investors in cannabis-based therapeutic delivery technology should monitor the prosecution of this application for potential licensing opportunities or competitive filings in the low-dose THC inhaler space. Pharmaceutical and medical device companies developing digital dose-delivery systems for controlled substances may find this application relevant to freedom-to-operate analyses.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

LOW DOSE THERAPEUTIC TREATMENT

Application US20260108542A1 Kind: A1 Apr 23, 2026

Assignee

Syqe Medical Ltd.

Inventors

Perry DAVIDSON, Seth KINDLER, Shlomo ALMOG, Binyamin SCHWARTZ, Aaron SCHORR, Daniella ATZMONY

Abstract

Some embodiments of the invention relate to a system for delivering to a subject at least one pre-determined amount of THC, the system comprising: a memory which stores a scheduled regimen for delivery of THC to the subject, the scheduled regimen defining: a maximal amount of THC to be delivered, the amount being 0.75 mg THC or less, and a time period within which that amount is delivered, the time period being 2 hours or longer; a decision module which decides, according to the scheduled regimen, if a delivery should take place; and an inhaler device for delivering THC to the subject, the inhaler device comprising a controller which carries out delivery of THC based on the decision made by the decision module.

CPC Classifications

A61K 31/658 A61K 9/008 A61M 11/042 A61M 15/0003 A61M 15/009 A61P 29/02 G16H 20/13 G16H 40/63 A61M 2205/52

Filing Date

2025-12-19

Application No.

19426146

View original document →

Get daily alerts for USPTO Patent Applications - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Draft
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application filing THC delivery system
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Medical Devices Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!